Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by PTBaileyon Dec 22, 2021 1:01pm

180 Views

Post# 34255063

Two different but related NR's

"Under the License Amendment, Claritas will now have world-wide rights to develop R-107 for the treatment of pulmonary diseases, including PAH and PPHN. The Company will shortly issue a separate press release providing details regarding the medical and business rationales for developing R-107 as a treatment for PPHN."

Unofficial Analysis
https://claritasinvestors.com/index.php?/articles.html/articles/unofficial-analysis-claritas-to-develop-r-107-for-treatment-of-pphn-a-potentially-fatal-pulmonary-disorder-in-newborns-r188/

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario